SANTA MONICA, CA / ACCESSWIRE / July 19, 2016 / Hatch Interactive Technologies Corp. (CSE: HAT) (OTC: HTTRF) (FRANKFURT: TQ42) (“Hatch Interactive” or the “Company”) is pleased to announce the appointment of digital media executive Sheila Romana to the Company’s Advisory Board.

With over 20 years’ experience in marketing & publicity, Sheila is a veteran at targeting male audiences and sports fans. As a former marketing executive at NBC, Sheila oversaw development and execution of large-scale national advertising campaigns for MSNBC, MSNBC.com, NBC Cable Networks, CNBC.com, and the NBC Olympic coverage.

As head of her own company, Romana Marketing Solutions | RMS, she has led campaigns for UFC, “The Walking Dead”, “Black Sails”, “Inglorious Basterds” and dozens of independent horror, action and sci-fi movies, and other male-skewing genres. Sheila graduated with a BBA, Marketing from the University of Wisconsin-Milwaukee – Lubar School of Business and holds an MBA from Arizona State University – W. P. Carey School of Business.

Sheila Romana commented, “With my experience in sports, film and television marketing, I look forward to bringing custom marketing solutions and digital cross-promotional campaigns to the Fandom Sports App.”

CEO Blair Naughty states, “Sheila is a very passionate marketing professional that offers advertising, marketing strategy, promotion, and product management. She has created some very innovative marketing initiatives in the sports and digital media world and we look forward to working with her to build on the Fandom Sports Media brand.”

About Hatch Interactive Technologies Corp.

Hatch Interactive Technologies is an aggregator, curator and producer of unique fan-focused content offered on a category-specific, social network and delivered through the Fandom Sports Media mobile app. We tap into the passion of fans by providing an engaging social platform for the world’s most enthusiastic sports fans to share, compare, moan, whine, gloat and trash talk about the sports, teams, players, fans and owners they love, hate and love to hate. Our unique approach will blend curated content with user- generated content while providing access to athletes and celebrities both on-line and at local sponsored events.

To find out more about Hatch, please contact investor relations at 604-346-7613.

You may also visit the Company’s website at www.hatchitech.com.

On Behalf of the Company

“Blair Naughty”

Blair Naughty, CEO

For additional Information:

Hatch Interactive Technologies Corp.
Blair Naughty
Tel: 604-346-7613.
Email: info@hatchitech.com

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at www.sedar.com).

The Company has no intention or obligation to update or revise any forward looking statements due to new information or events.

SOURCE: Hatch Interactive Technologies Corp.

ReleaseID: 442575

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Golden Enterprises, Inc. (“Golden Enterprises”) (NASDAQGM: GLDC) stock prior to July 19, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Golden Enterprises to Utz Quality Foods, Inc. for $12.00 in cash per Golden Enterprises share. To learn more about the action and your rights, go to: http://zlk.9nl.com/golden-enterprises-gldc. or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 442573

Surfers with Ear Problems can now be Protected by Surfears, While Shark Banz is a New Device Designed to Keep Sharks Away

SYDNEY, AU / ACCESSWIRE / July 19, 2016 / SurfboardFins.com.au, a company that specializes in bringing the latest equipment to surfers, recently announced its decision to expand its product range. The company is proud to introduce two new items: Surfears, a new gadget that protects surfers with ear problems, and Shark Banz, a shark-repelling tool that helps surfers navigate waters safely.

In addition to stocking Surfears and Shark Banz, the website is also offering clients the opportunity to buy surfboard fins online. Two companies, Fin Control System (FCS) and Futures Fins, create the detachable fins, which are available in four styles: reactor, performer, accelerator, and carver. Fin Control System and Future Fins’ products are created to accommodate the needs of surfers across all skill levels, and both brands are popular with amateurs and veterans alike.

In comparison to glassed-on fin systems, removable fin systems offers surfers a number of advantages such as sturdiness, easier control, and expense effectiveness. Boards are now more resilient because fins can be easily switched when broken, plus changing the number of fins allows surfers to explore speed, rotation, and stability choices. All of the variables can be changed on one board instead of maintaining several boards, allowing surfers to save money.

“To say that detachable fin systems have revolutionalised surfing is an understatement,” stated a representative of SurfboardFins.com.au.

“Since the introduction of these systems, surfers have actually experienced safer surfing and more. With the numerous alternatives offered today, each surfer has the opportunity to choose the ideal fin system for optimum enjoyment in the water.”

Individuals interested in learning more about SurfboardFins.com.au and its wide range of surfing accessories can visit the surfboard supplies website for additional information.

About SurfboardFins.com.au:

SurfboardFins.com.au is the cheapest online supplier of surfing accessories in Australia. The company supplies a full range of surfboard fins from the major manufacturers – FCS, Futures and Creatures of Leisure. Shipping worldwide and successfully supplying customers since 2010, the company’s main goal is to be the cheapest one-stop surf accessories shop and to stock a wide variety of hobby and outdoor products. SurfboardFins.com.au is continually sourcing new brands and products and adding these to its already growing online shop, with a commitment and focus on customer service—the highest quality in product at the lowest price. For more information, please visit http://surfboardsfins.com.au.

Contact:

Adam Condon
adam@seaworthy.com.au
(02) 9939-1270

SOURCE: SurfboardFins.com.au

ReleaseID: 442571

Photos can now be Uploaded in Eight Different Ways, Including Facebook, Gmail, Flickr, and Google Drive

LOS ANGELES, CA / ACCESSWIRE / July 19, 2016 / Q Canvas Prints, a company that specializes in creating custom canvas prints that reflect a number of personalities and styles, recently announced its decision to offer customers the option to upload photos and order prints. Photos stored on websites such as Facebook, Gmail, Flickr, Google Drive, and Picasa can now be uploaded and printed on canvas.

“Within seconds, you can see your photos in our virtual environments and know exactly what your canvas print will look like on the wall,” said a representative of Q Canvas Prints. “Every canvas comes ready to hang, especially because we use eight color printing on genuine artist canvas.”

To create a print, users only need to upload an image or select one from Q Canvas Print’s extensive gallery. Once selected, customers can import images and select the canvas size. Q Canvas Prints allows customers to view the artwork in several different settings, which can help them visualize the piece in different spaces of their home or office.

After specifying the print type, print size, and other additional customizations, customers can order the artwork. Checkout is simple: clients can either checkout as a guest or create an account for later use. Q Canvas Prints’ pieces are printed on tight and flat canvasses with solid faces; every frame is built with a solid face to support the canvas and keep it from deforming and loosening.

Should customers be unhappy with any piece ordered, Q Canvas Prints will gladly replace it or refund the cost. Q Canvas Prints encourages all customers with questions or comments about its services to contact them via the form available on its website.

Individuals interested in learning more about Q Canvas Prints and its work can visit the company’s website for additional information.

About Q Canvas Prints:

At Q Canvas Prints, customers’ purchases will always look as tight and flat as the day it was made. Every frame is built with a solid face to support the canvas and keep it from deforming and loosening. Every canvas comes ready to hang, as Q Canvas Prints uses eight-color printing on genuine artist canvas. For more information, please visit http://qcanvasprints.com.

Contact:

Robin Graham
admin@rocketfactor.com
(949) 555-2861

SOURCE: Q Canvas Prints

ReleaseID: 442570

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors
that a securities class action has been filed in the United States District Court Western District of Washington on behalf of those who purchased shares of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) and certain of its officers, during the period between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

Juno is a biopharmaceutical company founded in 2013 that is developing cell-based cancer immunotherapies. JCAR015, its leading product candidate, is currently in clinical trials.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Juno’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or partial disclosures regarding JCAR015’s safety and made public misrepresentations or failed to disclose material facts of the death of patients in its Phase 2 clinical trial.

In May 2016, a patient in the Phase 2 trial of JCAR015 died of a cerebral edema, a form of neurotoxicity. Two additional patients in the ROCKET trial died of cerebral edemas by early July, causing the FDA to issue a clinical hold which forced Defendants to reveal the truth on July 7, 2016, post-market. Following this news, Juno’s stock dropped $13.01 per share, or 31.87%, to close at $27.81 on July 8, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!juno/c3onh or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Juno, you have until September 12,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442525

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court, District of Massachusetts on behalf of those who purchased shares of Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ: CHMA) between July 15, 2015 and April 17, 2016 inclusive (the “Class Period”).

Chiasma is a biopharmaceutical company focused on developing and commercializing orphan medications to better meet the needs of patients and healthcare professionals.

Chiasma’s leading product is oral octreotide, Mycapssa, used to treat acromegaly, a condition resulting from excess growth hormone. As of June 2015, Chiasma had finished its multinational Phase 3 clinical trial of Mycapssa and submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for approval to market and sell Mycapssa. On or about July 15, 2016, Chiasma completed its IPO, issuing 6.4 million shares and raising approximately $102 million of net proceeds.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Chiasma’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Chiasma’s Phase 3 clinical trial for Mycapssa was not adequate to show effectiveness and for FDA approval; (2) Chiasma’s management of its suppliers was not adequate to avoid mistakes, thus delaying FDA approval; and (3) consequentially, Chiasma’s public statements were materially false and misleading at all relevant times.

On April 18, 2016, premarket, Chiasma announced that the FDA had issued a Complete Response Letter for Mycapssa’s NDA, explaining that the FDA did not see ample proof of efficacy to warrant approval and advising the Company to conduct another clinical trial to address this deficiency. The FDA also listed its apprehensions about certain aspects of the Company’s single-arm, open-label Phase 3 clinical trial and strongly recommended a randomized, double-blind and controlled trial that enrolls patients from the United States and for a long enough duration to ensure that control of disease activity is stable at the time point selected for the primary efficacy assessment. The FDA instructed that certain deficiencies that were found at a recent site inspection would also need to be resolved before approval.

Following this news, Chiasma stock dropped $6.42 per share, or 63.13%, to close at $3.75 on April 18, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!chma/ts6n9. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Chiasma you have until
August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442281

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of CPI Card Group, Inc. (“CPI” or the “Company”) (NASDAQ: PMTS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired CPI common stock in connection with CPI’s October 8, 2015 initial public offering (“IPO”), including purchasers of the common stock in the aftermarket.

CPI is a prominent provider of electronic payment cards and associated services, offering a single source for credit, debit and prepaid debit cards, including “EMV” (Europay, MasterCard and Visa) chip, personalization, instant issuance, fulfillment and mobile payment services.

The complaint alleges that at the time of the IPO, CPI had shipped over 100 million cards more than shipped in the second quarter and first part of the third quarter of 2015. Unbeknownst to investors at the time, this shipment created a massive backlog with those customers, which significantly reduced the demand for additional card shipments in the fourth quarter of 2015 and fiscal 2016. The unfavorable dealings and uncertainties linked with CPI’s largest customers’ inventory levels were likely to impact on CPI’s profitability and, therefore, should have been disclosed in the Registration Statement.

CPI sold 17.25 million shares of common stock during its IPO at $10 per share, raising $172.5 million. At the time the complaint was filed, CPI common stock was trading at about $4.70 per share – 53% less than the IPO price.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!cpi/edd1e or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CPI and purchased the common stock in or pursuant to CPI’s October 8, 2015 IPO, including purchasers of the common stock in the aftermarket (the “Class”) you have until August 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442282

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed on behalf of those who purchased shares of Stericycle, Inc. (“Stericycle” or the “Company”) (NASDAQ: SRCL & SRCLP), during the period between February 7, 2013 and April 28, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements to investors or failed to disclose that Stericycle artificially inflated its revenues and growth by routinely raising the rates it charges to smaller customers, thus violating its contracts with those customers.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Stericycle, you have until September 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442385